Univariate analysis for association with more than 1 treatment-related SAE
| Comparison . | Odds ratio . | 95% confidence interval, lower limit . | 95% confidence interval, upper limit . | Wald P value . |
|---|---|---|---|---|
| During any treatment phase | ||||
| Mantle cell histology vs follicular | 2.61 | 1.19 | 5.64 | .015 |
| Other B-NHL histology vs follicular | 0.75 | 0.40 | 1.36 | .348 |
| Other B-NHL histology vs mantle cell | 0.29 | 0.12 | 0.67 | .0036 |
| Age, y >65 vs ≤65 | 1.20 | 0.71 | 2.05 | .496 |
| Age, y ≥70 vs <70 | 1.26 | 0.73 | 2.17 | .398 |
| Age, y ≥80 vs <80 | 1.93 | 0.83 | 4.26 | .111 |
| Male vs female sex | 0.99 | 0.58 | 1.69 | .976 |
| Bendamustine line of treatment, 2-3 vs 1 | 1.17 | 0.65 | 2.07 | .602 |
| Bendamustine line of treatment, ≥4 vs 1 | 0.94 | 0.33 | 2.32 | .898 |
| ACE27 2-3 vs 0-1 | 1.60 | 0.89 | 2.81 | .107 |
| Preinduction ECOG PS score of 1 vs 0 | 1.55 | 0.85 | 2.90 | .1568 |
| Preinduction ECOG PS score of 2 vs 0 | 2.98 | 1.21 | 7.19 | .0154 |
| Preinduction ECOG PS score of 3 vs 0 | 2.21 | 0.45 | 8.70 | .2795 |
| Premaintenance ECOG PS score of 1 vs 0 | 5.27 | 1.95 | 16.87 | .0021 |
| Premaintenance ECOG PS score of 2 vs 0 | 9.76 | 1.92 | 50.82 | .0053 |
| Stage III vs II | 2.34 | 0.66 | 11.03 | .2207 |
| Stage IV vs II | 2.65 | 0.88 | 11.46 | .1231 |
| FLIPI score, moderate vs low | 1.97 | 0.60 | 7.71 | .2835 |
| FLIPI score, high vs low | 2.16 | 0.72 | 8.06 | .2000 |
| sMIPI score, moderate vs low | 0.67 | 0.08 | 6.59 | .7110 |
| sMIPI score, high vs low | 1.31 | 0.17 | 12.27 | .7960 |
| sMIPI score, not applicable | 0.36 | 0.06 | 2.80 | .2720 |
| Sex, male vs female | 0.99 | 0.58 | 1.69 | .976 |
| G-CSF prophylaxis, yes vs no | .02847 | |||
| Prolonged steroid use, yes vs no | .2938 | |||
| Prior fludarabine, yes vs no | .7243 | |||
| Antibiotic prophylaxis, yes vs no | .9282 | |||
| Induction phase | ||||
| Starting bendamustine dose, 50%-74% vs 100% | 0.93 | 0.21 | 3.04 | .91 |
| Starting bendamustine dose, 75%-99% vs 100% | 1.35 | 0.54 | 3.08 | .494 |
| Lymphocyte count, normal vs abnormal | 0.76 | 0.41 | 1.38 | .379 |
| Total globulins, normal vs abnormal | 2.43 | 1.11 | 5.40 | .0274 |
| Maintenance & follow-up phases | ||||
| Lymphocyte count, normal vs abnormal | 0.95 | 0.14 | 3.99 | .947 |
| Total globulins, normal vs abnormal | 1.20 | 0.29 | 5.56 | .806 |
| Comparison . | Odds ratio . | 95% confidence interval, lower limit . | 95% confidence interval, upper limit . | Wald P value . |
|---|---|---|---|---|
| During any treatment phase | ||||
| Mantle cell histology vs follicular | 2.61 | 1.19 | 5.64 | .015 |
| Other B-NHL histology vs follicular | 0.75 | 0.40 | 1.36 | .348 |
| Other B-NHL histology vs mantle cell | 0.29 | 0.12 | 0.67 | .0036 |
| Age, y >65 vs ≤65 | 1.20 | 0.71 | 2.05 | .496 |
| Age, y ≥70 vs <70 | 1.26 | 0.73 | 2.17 | .398 |
| Age, y ≥80 vs <80 | 1.93 | 0.83 | 4.26 | .111 |
| Male vs female sex | 0.99 | 0.58 | 1.69 | .976 |
| Bendamustine line of treatment, 2-3 vs 1 | 1.17 | 0.65 | 2.07 | .602 |
| Bendamustine line of treatment, ≥4 vs 1 | 0.94 | 0.33 | 2.32 | .898 |
| ACE27 2-3 vs 0-1 | 1.60 | 0.89 | 2.81 | .107 |
| Preinduction ECOG PS score of 1 vs 0 | 1.55 | 0.85 | 2.90 | .1568 |
| Preinduction ECOG PS score of 2 vs 0 | 2.98 | 1.21 | 7.19 | .0154 |
| Preinduction ECOG PS score of 3 vs 0 | 2.21 | 0.45 | 8.70 | .2795 |
| Premaintenance ECOG PS score of 1 vs 0 | 5.27 | 1.95 | 16.87 | .0021 |
| Premaintenance ECOG PS score of 2 vs 0 | 9.76 | 1.92 | 50.82 | .0053 |
| Stage III vs II | 2.34 | 0.66 | 11.03 | .2207 |
| Stage IV vs II | 2.65 | 0.88 | 11.46 | .1231 |
| FLIPI score, moderate vs low | 1.97 | 0.60 | 7.71 | .2835 |
| FLIPI score, high vs low | 2.16 | 0.72 | 8.06 | .2000 |
| sMIPI score, moderate vs low | 0.67 | 0.08 | 6.59 | .7110 |
| sMIPI score, high vs low | 1.31 | 0.17 | 12.27 | .7960 |
| sMIPI score, not applicable | 0.36 | 0.06 | 2.80 | .2720 |
| Sex, male vs female | 0.99 | 0.58 | 1.69 | .976 |
| G-CSF prophylaxis, yes vs no | .02847 | |||
| Prolonged steroid use, yes vs no | .2938 | |||
| Prior fludarabine, yes vs no | .7243 | |||
| Antibiotic prophylaxis, yes vs no | .9282 | |||
| Induction phase | ||||
| Starting bendamustine dose, 50%-74% vs 100% | 0.93 | 0.21 | 3.04 | .91 |
| Starting bendamustine dose, 75%-99% vs 100% | 1.35 | 0.54 | 3.08 | .494 |
| Lymphocyte count, normal vs abnormal | 0.76 | 0.41 | 1.38 | .379 |
| Total globulins, normal vs abnormal | 2.43 | 1.11 | 5.40 | .0274 |
| Maintenance & follow-up phases | ||||
| Lymphocyte count, normal vs abnormal | 0.95 | 0.14 | 3.99 | .947 |
| Total globulins, normal vs abnormal | 1.20 | 0.29 | 5.56 | .806 |
Wald P values are bold if P < .05.
FLIPI, Follicular Lymphoma International Prognostic Index; PS, performance status; sMIPI, simplified Mantle Cell Lymphoma International Prognostic Index.